Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Joly

Showing results (101-110 of 227) with videos related to

Pageof 23
Sort By:
Archives of Dermatology|April 18, 2012
Poor benefit/risk balance of intravenous immunoglobulins in DRESSPascal Joly, Baptiste Janela, Florence Tetart, et al.
Proteomics|August 8, 2006
Proteomic analysis of the autoantibody response following immunization with a single autoantigenHugo Mouquet, Laurent Drouot, Roland Charlionnet, et al.
The Journal of Investigative Dermatology|May 7, 2023
The Importance of Patient-Focused Drug Development in Pemphigus and PemphigoidMarc Yale, Patrick Dunn, Rebecca Strong, et al.
The British Journal of Dermatology|January 9, 2026
Persistence of anti-Desmoglein 3 Antibodies in Patients with Pemphigus Vulgaris in Clinical Remission is Associated with Restricted Isotype Diversity and Desmoglein 3 Ectodomain RecognitionBillal Tedbirt, Sébastien Calbo, Léopoldine Lebourgeois, et al.
The British Journal of Dermatology|March 10, 2026
Prevalence and Pathogenicity of Anti-SPCA1 and Anti-M3AchR Auto-antibodies in PemphigusBillal Tedbirt, Alexandre Lemieux, Maud Maho-Vaillant, et al.
Advanced Healthcare Materials|January 26, 2016
Click-Crosslinked Injectable Gelatin HydrogelsSandeep T Koshy, Rajiv M Desai, Pascal Joly, et al.
European Journal of Dermatology : EJD|March 5, 2019
Efficacy and safety of oral alitretinoin as treatment for chronic hand eczema in France: a real-life open-label studyBruno Halioua, Carle Paul, Philippe Berbis, et al.
Dermatology (Basel, Switzerland)|September 8, 2007
Neurological disorders in patients with bullous pemphigoidNadège Cordel, Olivier Chosidow, Marie-France Hellot, et al.
The New England Journal of Medicine|June 7, 2021
Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus VulgarisVictoria P Werth, Pascal Joly, Daniel Mimouni, et al.
Scientific Reports|December 15, 2015
Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcomeJulie Plée, Sébastien Le Jan, Jérôme Giustiniani, et al.
Pageof 23

Showing results (101-110 of 227) with videos related to

Sort By:
Pageof 23
Archives of Dermatology|April 18, 2012
Poor benefit/risk balance of intravenous immunoglobulins in DRESSPascal Joly, Baptiste Janela, Florence Tetart, et al.
Proteomics|August 8, 2006
Proteomic analysis of the autoantibody response following immunization with a single autoantigenHugo Mouquet, Laurent Drouot, Roland Charlionnet, et al.
The Journal of Investigative Dermatology|May 7, 2023
The Importance of Patient-Focused Drug Development in Pemphigus and PemphigoidMarc Yale, Patrick Dunn, Rebecca Strong, et al.
The British Journal of Dermatology|January 9, 2026
Persistence of anti-Desmoglein 3 Antibodies in Patients with Pemphigus Vulgaris in Clinical Remission is Associated with Restricted Isotype Diversity and Desmoglein 3 Ectodomain RecognitionBillal Tedbirt, Sébastien Calbo, Léopoldine Lebourgeois, et al.
The British Journal of Dermatology|March 10, 2026
Prevalence and Pathogenicity of Anti-SPCA1 and Anti-M3AchR Auto-antibodies in PemphigusBillal Tedbirt, Alexandre Lemieux, Maud Maho-Vaillant, et al.
Advanced Healthcare Materials|January 26, 2016
Click-Crosslinked Injectable Gelatin HydrogelsSandeep T Koshy, Rajiv M Desai, Pascal Joly, et al.
European Journal of Dermatology : EJD|March 5, 2019
Efficacy and safety of oral alitretinoin as treatment for chronic hand eczema in France: a real-life open-label studyBruno Halioua, Carle Paul, Philippe Berbis, et al.
Dermatology (Basel, Switzerland)|September 8, 2007
Neurological disorders in patients with bullous pemphigoidNadège Cordel, Olivier Chosidow, Marie-France Hellot, et al.
The New England Journal of Medicine|June 7, 2021
Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus VulgarisVictoria P Werth, Pascal Joly, Daniel Mimouni, et al.
Scientific Reports|December 15, 2015
Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcomeJulie Plée, Sébastien Le Jan, Jérôme Giustiniani, et al.
Pageof 23